drugset / Trial / NCT00452023
Pegasys® in Patients With Myeloproliferative Diseases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to see if Pegasys (IFN-alpha2a) can help to control the disease in patients with ET, PV, AMM/MF, and Ph-negative CML. The safety of this treatment will also be studied.
Timeline
- Start
- 2005-04-07
- Primary completion
- 2023-05-26
- Completion
- 2023-05-26
Publications
- Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017 Nov 9;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017.
- Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr;4(4):e165-e175. doi: 10.1016/S2352-3026(17)30030-3. Epub 2017 Mar 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon | Protein / enzyme biologic | 90 ug | Subcutaneous |
| Subject | Interferon | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Interferon | Protein / enzyme biologic | 270 ug | Subcutaneous |
| Subject | Interferon | Protein / enzyme biologic | 360 ug | Subcutaneous |
| Subject | Interferon | Protein / enzyme biologic | 450 ug | Subcutaneous |